Zuellig Pharma
Concise Prescribing Info
Adults w/ wild-type RAS metastatic CRC (mCRC): 1st-line in combination w/ FOLFOX or FOLFIRI; 2nd-line in combination w/ FOLFIRI for patients who have received 1st-line fluoropyrimidine-based chemotherapy (excluding irinotecan). Monotherapy after failure of fluoropyrimidine-, oxaliplatin- & irinotecan-containing chemotherapy regimens.
Dosage/Direction for Use
6 mg/kg IV infusion once every 2 wk.
History of severe or life-threatening hypersensitivity reactions. Interstitial pneumonitis or pulmonary fibrosis. Combination w/ oxaliplatin-based chemotherapy when mutant RAS mCRC or RAS status is unknown.
Special Precautions
Hypersensitivity; infusion-related reactions. Not to be administered as IV push or bolus. Withhold or discontinue if dermatologic or soft tissue toxicity associated w/ severe or life-threatening inflammatory or infectious complications occurs. Acute onset or worsening pulmonary symptoms, history of interstitial pneumonitis or pulmonary fibrosis; severe diarrhoea & dehydration; history of keratitis, ulcerative keratitis or severe dry eye. Assess patients w/ ECOG 2 performance status prior to treatment. Monitor for inflammatory or infectious sequelae development; hypomagnesemia & accompanying hypocalcemia & electrolytes prior to, during & up to 8 wk after therapy. Contact lens users. Limit sun exposure. May affect ability to drive & use machines. Not to be used w/ bevacizumab-containing chemotherapy. Avoid combination w/ IFL. Acute renal failure. Renal or hepatic impairment. May affect female fertility. Women of childbearing potential should use effective contraception during & for 2 mth after last dose. Pregnancy. Not to be used during lactation. Elderly ≥65 yr.
Adverse Reactions
Conjunctivitis, paronychia; anaemia; hypokalaemia, hypomagnesaemia, decreased appetite; insomnia; dyspnoea, cough; GI disorders; skin & SC tissue disorders; back pain; fatigue, pyrexia, asthenia, mucosal inflammation, peripheral oedema; decreased wt. Pustular rash; cellulitis, UTI, folliculitis, localised infection; leucopenia; hypersensitivity; hypocalcaemia, dehydration, hyperglycaemia, hypophosphataemia; anxiety; headache, dizziness; eye disorders; tachycardia; DVT, hypotension, HTN, flushing; pulmonary embolism, epistaxis; pain in extremity; chest pain, pain, chills; decreased blood Mg.
Drug Interactions
High incidence of severe diarrhoea w/ IFL. Increased toxicity w/ bevacizumab & chemotherapy.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01FE02 - panitumumab ; Belongs to the class of EGFR (Epidermal Growth Factor Receptor) inhibitors. Used in the treatment of cancer.
Vectibix soln for infusion 20 mg/mL
5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in